Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBF-015 in Huntington's Disease
2023-505241-10-00Phase 2Completed
- Sponsor
- Medibiofarma
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MBF-015 in Huntington disease (HD), sponsored by Medibiofarma. Primary endpoint: Safety and tolerability of MBF-015 over 28 days. Started Sep 2023; status: completed.
02
Drugs
MBF-015
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2023-505241-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505241-10-00.